

# Michel P Coleman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1888034/publications.pdf>

Version: 2024-02-01

361  
papers

34,828  
citations

3721

89  
h-index

4101

175  
g-index

367  
all docs

367  
docs citations

367  
times ranked

34651  
citing authors

#	ARTICLE	IF	CITATIONS
1	Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1â€578â€5482 adults diagnosed during 2000â€2014 in 59 countries (CONCORD-3). <i>British Journal of Dermatology</i> , 2022, 187, 364-380.	1.4	17
2	Occupation and COVID-19 mortality in England: a national linked data study of 14.3 million adults. <i>Occupational and Environmental Medicine</i> , 2022, 79, 433-441.	1.3	72
3	Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000â€14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 409-431.	2.7	24
4	Excess mortality among essential workers in England and Wales during the COVID-19 pandemic. <i>Journal of Epidemiology and Community Health</i> , 2022, 76, 660-666.	2.0	15
5	Survival from five common cancers in Georgia, 2015â€2019 (CONCORD). <i>Cancer Epidemiology</i> , 2022, 79, 102190.	0.8	2
6	World-wide trends in net survival from pancreatic cancer by morphological sub-type: An analysis of 1,258,329 adults diagnosed in 58 countries during 2000â€2014 (CONCORD-3). <i>Cancer Epidemiology</i> , 2022, 80, 102196.	0.8	3
7	Disparities in Cancer Survival in Adults in Europe: The CONCORD Programme. , 2021, , 159-178.		0
8	Social Disparities in Survival from Breast Cancer in Europe. , 2021, , 71-111.		1
9	The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). <i>Neuro-Oncology</i> , 2021, 23, 1765-1776.	0.6	21
10	Are socio-economic inequalities in breast cancer survival explained by peri-diagnostic factors?. <i>BMC Cancer</i> , 2021, 21, 485.	1.1	7
11	Disparities in cervical cancer survival in the United States by race and stage at diagnosis: An analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3). <i>Gynecologic Oncology</i> , 2021, 163, 305-311.	0.6	13
12	The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 709-722.	3.7	52
13	Ethnic, racial and socioeconomic disparities in breast cancer survival in two Brazilian capitals between 1996 and 2012. <i>Cancer Epidemiology</i> , 2021, 75, 102048.	0.8	9
14	Global Trends in Survival From Astrocytic Tumors in Adolescents and Young Adults: A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa049.	1.4	5
15	Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa078.	1.4	8
16	Fleshing out the data: when epidemiological researchers engage with patients and carers. <i>Learning lessons from a patient involvement activity</i> . <i>BMJ Open</i> , 2020, 10, e036311.	0.8	3
17	Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: A population-based study. <i>Pancreatology</i> , 2020, 20, 454-461.	0.5	18
18	Sustainable care for children with cancer: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2020, 21, e185-e224.	5.1	177

#	ARTICLE	IF	CITATIONS
19	Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review. <i>Journal of Global Oncology</i> , 2019, 5, 1-25.	0.5	37
20	The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	18
21	Colorectal cancer incidence among young adults in England: Trends by anatomical sub-site and deprivation. <i>PLoS ONE</i> , 2019, 14, e0225547.	1.1	28
22	Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. <i>Lancet Oncology</i> , 2019, 20, 74-87.	5.1	98
23	Childhood cancer burden: a review of global estimates. <i>Lancet Oncology</i> , 2019, 20, e42-e53.	5.1	237
24	A Novel Approach to Obtain Follow-up Data on the Vital Status of Registered Cancer Patients: The Kuwait Cancer Registry Experience. <i>gulf journal of oncology</i> , 2019, 1, 31-38.	0.2	1
25	Cancer survival trends in Kuwait, 2000-2013: A population-based study. <i>gulf journal of oncology</i> , 2019, 1, 39-52.	0.2	2
26	Conference report: improving outcomes for gastrointestinal cancer in the UK. <i>Frontline Gastroenterology</i> , 2018, 9, 49-61.	0.9	2
27	Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37.5 million patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. <i>Lancet</i> , 2018, 391, 1023-1075.	6.3	3,228
28	Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research. <i>British Journal of Cancer</i> , 2018, 118, 733-737.	2.9	5
29	Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996-2013: population based study. <i>BMJ: British Medical Journal</i> , 2018, 360, k764.	2.4	88
30	Worldwide trends in survival from adult glioma 2000-2014 (CONCORD-3): Impact of morphology. <i>Annals of Oncology</i> , 2018, 29, viii125.	0.6	1
31	Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): Preliminary findings and plans for further research. <i>Annals of Oncology</i> , 2018, 29, viii574.	0.6	0
32	Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients diagnosed during 1995-2009. <i>Cancer</i> , 2018, 124, 3856-3867.	2.0	33
33	Reply to Colon cancer survival in the US Department of Veterans Affairs by race and stage: 2001 through 2009. <i>Cancer</i> , 2018, 124, 2859-2860.	2.0	1
34	Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013. <i>BMC Cancer</i> , 2018, 18, 492.	1.1	21
35	How Do Biological Characteristics of Primary Intracranial Tumors Affect Their Clinical Presentation in Children and Young Adults?. <i>Journal of Child Neurology</i> , 2018, 33, 503-511.	0.7	2
36	Which indicators of early cancer diagnosis from population-based data sources are associated with short-term mortality and survival?. <i>Cancer Epidemiology</i> , 2018, 56, 161-170.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. <i>Lancet Haematology</i> , 2017, 4, e202-e217.	2.2	141
38	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EURO-CARE-5. <i>European Journal of Cancer</i> , 2017, 77, 140-152.	1.3	72
39	Trends in net survival from esophageal cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S24-S31.	0.6	20
40	Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S100-S106.	0.6	0
41	Trends in net survival lung cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S70-S76.	0.6	9
42	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. <i>European Journal of Cancer Prevention</i> , 2017, 26, S9-S15.	0.6	7
43	Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S114-S120.	0.6	4
44	Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S48-S55.	0.6	14
45	Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S56-S62.	0.6	3
46	Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). <i>Gynecologic Oncology</i> , 2017, 144, 396-404.	0.6	93
47	The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). <i>Gynecologic Oncology</i> , 2017, 144, 405-413.	0.6	93
48	Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EURO-CARE-5 study. <i>European Journal of Cancer</i> , 2017, 84, 335-353.	1.3	29
49	Reply to correspondence “Do big numbers assure high-quality of data?”. <i>Lancet Haematology</i> , 2017, 4, e410.	2.2	0
50	Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S85-S91.	0.6	9
51	Trends in net survival from kidney cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S121-S127.	0.6	3
52	Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S77-S84.	0.6	13
53	Trends in net survival from cervical cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S92-S99.	0.6	5
54	Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S40-S47.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Trends in net survival from head and neck cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S16-S23.	0.6	7
56	Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S32-S39.	0.6	4
57	Population-based cancer survival in the United States: Data, quality control, and statistical methods. <i>Cancer</i> , 2017, 123, 4982-4993.	2.0	27
58	Rectal cancer survival in the United States by race and stage, 2001 to 2009: Findings from the CONCORD-2 study. <i>Cancer</i> , 2017, 123, 5037-5058.	2.0	23
59	Colon cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. <i>Cancer</i> , 2017, 123, 5014-5036.	2.0	108
60	Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S63-S69.	0.6	15
61	Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S107-S113.	0.6	10
62	Geographical variability in survival of European children with central nervous system tumours. <i>European Journal of Cancer</i> , 2017, 82, 137-148.	1.3	33
63	Life tables for global surveillance of cancer survival (the CONCORD programme): data sources and methods. <i>BMC Cancer</i> , 2017, 17, 159.	1.1	28
64	Trends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material. <i>European Journal of Cancer Prevention</i> , 2017, 26, S3-S8.	0.6	3
65	The global burden of women's cancers: a grand challenge in global health. <i>Lancet</i> , The, 2017, 389, 847-860.	6.3	666
66	Where are the opportunities for an earlier diagnosis of primary intracranial tumours in children and young adults?. <i>European Journal of Paediatric Neurology</i> , 2017, 21, 388-395.	0.7	10
67	Population-based cancer survival (2001 to 2009) in the United States: Findings from the CONCORD-2 study. <i>Cancer</i> , 2017, 123, 4963-4968.	2.0	18
68	Public health surveillance of cancer survival in the United States and worldwide: The contribution of the CONCORD programme. <i>Cancer</i> , 2017, 123, 4977-4981.	2.0	19
69	Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study. <i>Cancer</i> , 2017, 123, 5178-5189.	2.0	49
70	Data Quality in Rare Cancers Registration: The Report of the RARECARE Data Quality Study. <i>Tumori</i> , 2017, 103, 22-32.	0.6	26
71	Are international differences in breast cancer survival between Australia and the UK present amongst both screen-detected women and non-screen-detected women? survival estimates for women diagnosed in Western, Middle and New South Wales 1997-2006. <i>International Journal of Cancer</i> , 2016, 138, 2404-2414.	2.3	8
72	Do cancer survival statistics for every hospital make sense?. <i>Lancet Oncology</i> , The, 2016, 17, 1192-1194.	5.1	8

#	ARTICLE	IF	CITATIONS
73	Adjusting for overdispersion in piecewise exponential regression models to estimate excess mortality rate in population-based research. <i>BMC Medical Research Methodology</i> , 2016, 16, 129.	1.4	10
74	Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988â€“2011: a populationâ€“based study. <i>British Journal of Haematology</i> , 2016, 173, 292-302.	1.2	20
75	Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (<scp>UK</scp>) and New South Wales (Australia): Women diagnosed 1997â€“2006. <i>International Journal of Cancer</i> , 2016, 138, 2396-2403.	2.3	21
76	The effect of multiple primary rules on cancer incidence rates and trends. <i>Cancer Causes and Control</i> , 2016, 27, 377-390.	0.8	30
77	Survival of male genital cancers (prostate, testis and penis) in Europe 1999â€“2007: Results from the EUROCARE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2206-2216.	1.3	82
78	Age and case mix-standardised survival for all cancer patients in Europe 1999â€“2007: Results of EUROCARE-5, a population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2120-2129.	1.3	66
79	How many cancer deaths could New Zealand avoid if fiveâ€“year relative survival ratios were the same as in Australia?. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 157-161.	0.8	10
80	Cancer survival: the CONCORD-2 study â€“ Authors' reply. <i>Lancet, The</i> , 2015, 386, 429-430.	6.3	6
81	Cancer survival in <scp>C</scp>hina, 2003â€“2005: A populationâ€“based study. <i>International Journal of Cancer</i> , 2015, 136, 1921-1930.	2.3	585
82	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015, 26, 300-306.	0.6	77
83	The impact of age at diagnosis on socioeconomic inequalities in adult cancer survival in England. <i>Cancer Epidemiology</i> , 2015, 39, 641-649.	0.8	44
84	Pattern of symptoms and signs of primary intracranial tumours in children and young adults: a record linkage study. <i>Archives of Disease in Childhood</i> , 2015, 100, 1115-1122.	1.0	26
85	Cancer: the elephant in the room. <i>Lancet, The</i> , 2015, 385, 1047-1048.	6.3	14
86	Urinary tract cancer survival in Europe 1999â€“2007: Results of the population-based study EUROCARE-5. <i>European Journal of Cancer</i> , 2015, 51, 2217-2230.	1.3	75
87	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2130-2143.	1.3	344
88	Survival for oesophageal, stomach and small intestine cancers in Europe 1999â€“2007: Results from EUROCARE-5. <i>European Journal of Cancer</i> , 2015, 51, 2144-2157.	1.3	138
89	The EUROCARE-5 study on cancer survival in Europe 1999â€“2007: Database, quality checks and statistical analysis methods. <i>European Journal of Cancer</i> , 2015, 51, 2104-2119.	1.3	97
90	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999â€“2007: Results of EUROCARE-5. <i>European Journal of Cancer</i> , 2015, 51, 2169-2178.	1.3	115

#	ARTICLE	IF	CITATIONS
91	Is England closing the international gap in cancer survival?. British Journal of Cancer, 2015, 113, 848-860.	2.9	97
92	Cancer survival differences between South Asians and non-South Asians of England in 1986-2004, accounting for age at diagnosis and deprivation. British Journal of Cancer, 2015, 113, 173-181.	2.9	23
93	40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet, The, 2015, 385, 1206-1218.	6.3	345
94	Global surveillance of cancer survival 1995-2009: analysis of individual data for 25-676-887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, The, 2015, 385, 977-1010.	6.3	1,863
95	No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. British Journal of Cancer, 2014, 111, 589-597.	2.9	14
96	Optimal use of staging data in international comparisons of colorectal cancer survival. Acta Oncologica, 2014, 53, 847-848.	0.8	1
97	The impact of life tables adjusted for smoking on the socio-economic difference in net survival for laryngeal and lung cancer. British Journal of Cancer, 2014, 111, 195-202.	2.9	48
98	Funnel plots for population-based cancer survival: principles, methods and applications. Statistics in Medicine, 2014, 33, 1070-1080.	0.8	22
99	Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet, The, 2014, 383, 564-573.	6.3	118
100	Reply to comments by Dr. Frisch and Dr. Van Howe. Cancer Causes and Control, 2014, 25, 407-408.	0.8	1
101	Cancer survival in Europe 1999-2007 by country and age: results of EURO-CARE-5-a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	5.1	1,554
102	Cancer incidence, survival and mortality: Explaining the concepts. International Journal of Cancer, 2014, 135, 1774-1782.	2.3	114
103	Control of data quality for population-based cancer survival analysis. Cancer Epidemiology, 2014, 38, 314-320.	0.8	22
104	Comparability of stage data in cancer registries in six countries: Lessons from the International Cancer Benchmarking Partnership. International Journal of Cancer, 2013, 132, 676-685.	2.3	108
105	Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes and Control, 2013, 24, 2169-2176.	0.8	97
106	Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. International Journal of Cancer, 2013, 132, 2404-2412.	2.3	69
107	War on cancer and the influence of the medical-industrial complex. Journal of Cancer Policy, 2013, 1, e31-e34.	0.6	21
108	The International Cancer Benchmarking Partnership: An international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. Health Policy, 2013, 112, 148-155.	1.4	87

#	ARTICLE	IF	CITATIONS
109	Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. European Journal of Cancer, 2013, 49, 2565-2578.	1.3	91
110	Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax, 2013, 68, 551-564.	2.7	428
111	Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. European Journal of Cancer, 2013, 49, 684-695.	1.3	519
112	Breast cancer survival in the US and Europe: A CONCORD high-resolution study. International Journal of Cancer, 2013, 132, 1170-1181.	2.3	100
113	Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open, 2013, 3, e003055.	0.8	72
114	Health Systems Performance and Cancer Outcomes. Journal of the National Cancer Institute Monographs, 2013, 2013, 7-12.	0.9	24
115	Cancer incidence in South Asian migrants to England, 1986-2004: Unraveling ethnic from socioeconomic differentials. International Journal of Cancer, 2013, 132, 1886-1894.	2.3	37
116	Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000-2007. Acta Oncologica, 2013, 52, 919-932.	0.8	163
117	Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. British Journal of Cancer, 2013, 108, 1195-1208.	2.9	181
118	Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 2013, 98, 744-752.	1.7	35
119	Act now against new NHS competition regulations. BMJ, The, 2013, 346, f1819-f1819.	3.0	6
120	Reply to investigating changes over time in socioeconomic gaps in cancer survival: does choice of approach matter?. Annals of Oncology, 2012, 23, 279-280.	0.6	1
121	Letter from America. Lancet, The, 2012, 379, 1288.	6.3	3
122	Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership. Gynecologic Oncology, 2012, 127, 75-82.	0.6	165
123	Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade. Acta Oncologica, 2012, 51, 441-453.	0.8	88
124	Socio-economic inequalities in testicular cancer survival within two clinical studies. Cancer Epidemiology, 2012, 36, 217-221.	0.8	11
125	Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. European Journal of Cancer, 2012, 48, 159-169.	1.3	37
126	Rare cancers of the head and neck area in Europe. European Journal of Cancer, 2012, 48, 783-796.	1.3	55



#	ARTICLE	IF	CITATIONS
127	Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1167-1175.	1.3	71
128	How many deaths would be avoidable if socioeconomic inequalities in cancer survival in England were eliminated? A national population-based study, 1996-2006. <i>European Journal of Cancer</i> , 2012, 48, 270-278.	1.3	69
129	Incidence and survival of rare urogenital cancers in Europe. <i>European Journal of Cancer</i> , 2012, 48, 456-464.	1.3	132
130	Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. <i>European Journal of Cancer</i> , 2012, 48, 1417-1424.	1.3	42
131	Epidemiology of glial and non-glial brain tumours in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1532-1542.	1.3	248
132	Embryonal cancers in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1425-1433.	1.3	39
133	Carcinoma of endocrine organs: Results of the RARECARE project. <i>European Journal of Cancer</i> , 2012, 48, 1923-1931.	1.3	43
134	Invasive extramammary Paget's disease and the risk for secondary tumours in Europe. <i>European Journal of Surgical Oncology</i> , 2012, 38, 214-221.	0.5	63
135	Oesophageal cancer survival in Europe: A EURO-CARE-4 study. <i>Cancer Epidemiology</i> , 2012, 36, 505-512.	0.8	108
136	Incidence, survival and prevalence of myeloid malignancies in Europe. <i>European Journal of Cancer</i> , 2012, 48, 3257-3266.	1.3	158
137	Survival of European patients with central nervous system tumors. <i>International Journal of Cancer</i> , 2012, 131, 173-185.	2.3	64
138	Full dates (day, month, year) should be used in population-based cancer survival studies. <i>International Journal of Cancer</i> , 2012, 131, E1120-4.	2.3	15
139	Trends and inequalities in laryngeal cancer survival in men and women: England and Wales 1991-2006. <i>Oral Oncology</i> , 2012, 48, 284-289.	0.8	23
140	Rare cancers are not so rare: The rare cancer burden in Europe. <i>European Journal of Cancer</i> , 2011, 47, 2493-2511.	1.3	573
141	Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the) <i>Lancet</i> , The, 2011, 377, 127-138.	6.3	999
142	Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK - Authors' reply. <i>Lancet</i> , The, 2011, 377, 1149-1150.	6.3	3
143	Rebuttal to editorial saying cancer survival statistics are misleading. <i>BMJ: British Medical Journal</i> , 2011, 343, d4214-d4214.	2.4	4
144	Evidence against the proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer Registry data. <i>BMJ: British Medical Journal</i> , 2011, 342, d3399-d3399.	2.4	41

#	ARTICLE	IF	CITATIONS
145	Prognoses for head and neck cancers in Europe diagnosed in 1995â€“1999: a population-based study. <i>Annals of Oncology</i> , 2011, 22, 165-174.	0.6	35
146	Changes over time in socioeconomic inequalities in breast and rectal cancer survival in England and Wales during a 32-year period (1973â€“2004): the potential role of health care. <i>Annals of Oncology</i> , 2011, 22, 1661-1666.	0.6	44
147	Harmonization may be counterproductive—at least for parts of Europe where public health research operates effectively. <i>European Journal of Public Health</i> , 2011, 21, 686-687.	0.1	16
148	Thirty-day postoperative mortality after colorectal cancer surgery in England. <i>Gut</i> , 2011, 60, 806-813.	6.1	238
149	Geographical variation in cancer survival in England, 1991-2006: an analysis by Cancer Network. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, 1044-1052.	2.0	23
150	Inequalities in cancer survival: Spearhead Primary Care Trusts are appropriate geographic units of analyses. <i>Health Statistics Quarterly</i> , 2010, 48, 81-90.	0.9	0
151	Survival from twenty adult cancers in the UK and Republic of Ireland in the late twentieth century. <i>Health Statistics Quarterly</i> , 2010, 46, 7-26.	0.9	2
152	The state of the art of cancer control in 30 European countries in 2008. <i>International Journal of Cancer</i> , 2010, 126, 2700-2715.	2.3	53
153	Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. <i>British Journal of Cancer</i> , 2010, 103, 446-453.	2.9	171
154	Differences in breast cancer incidence in Australia and England by age, extent of disease and deprivation status: women diagnosed 1980â€“2002. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 206-213.	0.8	5
155	Does the timing of comorbidity affect colorectal cancer survival? A population based study. <i>Postgraduate Medical Journal</i> , 2010, 86, 73-78.	0.9	19
156	Leukaemia survival trends in children with Down's syndrome in Great Britain, 1971-2000: a population-based study. <i>Journal of Epidemiology and Community Health</i> , 2010, 64, 604-609.	2.0	4
157	Two countries divided by a common language: health systems in the UK and USA. <i>Journal of the Royal Society of Medicine</i> , 2010, 103, 283-287.	1.1	82
158	Commentary: Estimating cancer survival—which is the right approach?. <i>International Journal of Epidemiology</i> , 2010, 39, 611-612.	0.9	4
159	Carcinoid Tumors of the Gastrointestinal Tract: Trends in Incidence in England Since 1971. <i>American Journal of Gastroenterology</i> , 2010, 105, 2563-2569.	0.2	229
160	Modelling relative survival in the presence of incomplete data: a tutorial. <i>International Journal of Epidemiology</i> , 2010, 39, 118-128.	0.9	91
161	Lung cancer in young women remains rare. <i>Lung Cancer</i> , 2010, 67, 124-125.	0.9	2
162	Cancer mortality in ethnic South Asian migrants in England and Wales (1993â€“2003): patterns in the overall population and in first and subsequent generations. <i>British Journal of Cancer</i> , 2010, 102, 1438-1443.	2.9	31

#	ARTICLE	IF	CITATIONS
163	Cancer survival in the developing world. <i>Lancet Oncology</i> , The, 2010, 11, 110-111.	5.1	12
164	International collaborations in cancer control and the Third International Cancer Control Congress. <i>Tumori</i> , 2009, 95, 579-596.	0.6	11
165	Cancer control-planning and monitoring population-based systems. <i>Tumori</i> , 2009, 95, 568-578.	0.6	16
166	What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?. <i>British Journal of Cancer</i> , 2009, 101, S115-S124.	2.9	148
167	â€Cureâ€™ from breast cancer among two populations of women followed for 23 years after diagnosis. <i>Annals of Oncology</i> , 2009, 20, 1331-1336.	0.6	30
168	Large differences in patterns of breast cancer survival between Australia and England: A comparative study using cancer registry data. <i>International Journal of Cancer</i> , 2009, 124, 2391-2399.	2.3	18
169	Regional differences in populationâ€based cancer survival between six prefectures in Japan: Application of relative survival models with funnel plots. <i>Cancer Science</i> , 2009, 100, 1306-1311.	1.7	12
170	The EURO CARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. <i>European Journal of Cancer</i> , 2009, 45, 909-930.	1.3	120
171	Long-term survival expectations of cancer patients in Europe in 2000â€2002. <i>European Journal of Cancer</i> , 2009, 45, 1028-1041.	1.3	87
172	The advantage of women in cancer survival: An analysis of EURO CARE-4 data. <i>European Journal of Cancer</i> , 2009, 45, 1017-1027.	1.3	233
173	EURO CARE-4. Survival of cancer patients diagnosed in 1995â€1999. Results and commentary. <i>European Journal of Cancer</i> , 2009, 45, 931-991.	1.3	740
174	The cancer survival gap between elderly and middle-aged patients in Europe is widening. <i>European Journal of Cancer</i> , 2009, 45, 1006-1016.	1.3	186
175	Survival trends in European cancer patients diagnosed from 1988 to 1999. <i>European Journal of Cancer</i> , 2009, 45, 1042-1066.	1.3	133
176	Multiple tumours in survival estimates. <i>European Journal of Cancer</i> , 2009, 45, 1080-1094.	1.3	109
177	The cure of cancer: A European perspective. <i>European Journal of Cancer</i> , 2009, 45, 1067-1079.	1.3	80
178	Survival of European children and young adults with cancer diagnosed 1995â€2002. <i>European Journal of Cancer</i> , 2009, 45, 992-1005.	1.3	442
179	Comparative cancer survival information in Europe. <i>European Journal of Cancer</i> , 2009, 45, 901-908.	1.3	123
180	Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. <i>Lancet Oncology</i> , The, 2009, 10, 351-369.	5.1	156

#	ARTICLE	IF	CITATIONS
181	Trends in cancer survival in Spearhead Primary Care Trusts in England,1998â€“2004. Health Statistics Quarterly, 2009, 41, 7-12.	0.9	10
182	Trends in Cancer Incidence, Survival and Mortality. , 2009, , 1-15.		270
183	Childhood leukaemia: long-term excess mortality and the proportion â€œcuredâ€™. British Journal of Cancer, 2008, 99, 219-223.	2.9	23
184	Cancer survival in England and Wales at the end of the 20th century. British Journal of Cancer, 2008, 99, S2-S10.	2.9	105
185	Survival from cancer of the oesophagus in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S11-S13.	2.9	14
186	Survival from cancer of the stomach in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S16-S18.	2.9	4
187	Survival from cancer of the pancreas in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S21-S23.	2.9	26
188	Survival from cancer of the colon in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S26-S29.	2.9	19
189	Survival from cancer of the rectum in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S30-S32.	2.9	25
190	Survival from cancer of the larynx in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S35-S37.	2.9	30
191	Survival from cancer of the lung in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S40-S42.	2.9	26
192	Survival from melanoma of the skin in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S47-S49.	2.9	11
193	Survival from cancer of the breast in women in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S53-S55.	2.9	28
194	Survival from cancer of the uterine cervix in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S59-S62.	2.9	4
195	Survival from cancer of the uterus in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S65-S67.	2.9	16
196	Survival from cancer of the ovary in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S70-S72.	2.9	16
197	Survival from prostate cancer in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S75-S77.	2.9	21
198	Survival from testicular cancer in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S80-S82.	2.9	18

#	ARTICLE	IF	CITATIONS
199	Survival from bladder cancer in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S86-S89.	2.9	31
200	Survival from cancers of the kidney and ureter in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S93-S95.	2.9	5
201	Survival from brain tumours in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S98-S101.	2.9	24
202	Survival from non-Hodgkin lymphoma in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S104-S106.	2.9	8
203	Survival from multiple myeloma in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S110-S112.	2.9	11
204	Survival from adult leukaemia in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S116-S118.	2.9	3
205	No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial. British Journal of Cancer, 2008, 99, 1923-1928.	2.9	36
206	Comparative indicators for cancer network management in England: Availability, characteristics and presentation. BMC Health Services Research, 2008, 8, 45.	0.9	15
207	Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. European Journal of Cancer, 2008, 44, 579-587.	1.3	32
208	Improving cancer control in the European Union: Conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007. European Journal of Cancer, 2008, 44, 1457-1462.	1.3	62
209	Cancer screening: Evidence and practice in Europe 2008. European Journal of Cancer, 2008, 44, 1404-1413.	1.3	100
210	Making progress against cancer in Europe in 2008. European Journal of Cancer, 2008, 44, 1451-1456.	1.3	53
211	Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncology, The, 2008, 9, 730-756.	5.1	1,059
212	Continuing Rapid Increase in Esophageal Adenocarcinoma in England and Wales. American Journal of Gastroenterology, 2008, 103, 2694-2699.	0.2	239
213	Would compliance with cancer care standards improve survival for breast, colorectal and lung cancers?. Journal of Epidemiology and Community Health, 2008, 62, 650-654.	2.0	24
214	Is the performance of cancer services influenced more by hospital factors or by specialization?. Journal of Public Health, 2008, 30, 69-74.	1.0	9
215	Life Tables for World-Wide Comparison of Relative Survival for Cancer (CONCORD Study). Tumori, 2008, 94, 658-668.	0.6	36
216	Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori, 2008, 94, 658-68.	0.6	21

#	ARTICLE	IF	CITATIONS
217	Increasing incidence of childhood leukaemia: a controversy re-examined. British Journal of Cancer, 2007, 97, 1009-1012.	2.9	53
218	Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1â€“75). Annals of Oncology, 2007, 18, 1433-1435.	0.6	9
219	Commentary: Is epidemiology really dead, anyway? * A look back at Kenneth Rothman's 'The rise and fall of epidemiology, 1950 2000 AD'. International Journal of Epidemiology, 2007, 36, 719-723.	0.9	2
220	Cancer Survival Trends in Osaka, Japan: the Influence of Age and Stage at Diagnosis. Japanese Journal of Clinical Oncology, 2007, 37, 452-458.	0.6	15
221	Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century. American Journal of Gastroenterology, 2007, 102, 1661-1670.	0.2	121
222	Reed Elsevier and the arms trade revisited. Lancet, The, 2007, 369, 987.	6.3	1
223	Survival from Uveal Melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiology, 2007, 14, 3-8.	0.8	44
224	Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study. Gastroenterology, 2007, 132, 899-904.	0.6	109
225	Predicted trends in long-term breast cancer survival in England and Wales. British Journal of Cancer, 2007, 96, 1135-1138.	2.9	17
226	Socioeconomic inequalities in cancer survival in Scotland 1986â€“2000. British Journal of Cancer, 2007, 97, 999-1004.	2.9	84
227	Trends in cervical cancer survival in Europe, 1983â€“1994: A population-based study. Gynecologic Oncology, 2007, 105, 609-619.	0.6	29
228	Cancer survival indicators by Cancer Network: a methodological perspective. Health Statistics Quarterly, 2007, , 36-41.	0.9	2
229	Survival from rare cancer in adults: a population-based study. Lancet Oncology, The, 2006, 7, 132-140.	5.1	120
230	Bradford NHS Trust and Panorama. Lancet, The, 2006, 368, 730-731.	6.3	1
231	Survival from rectal and anal cancers in England and Wales, 1986â€“2001. European Journal of Cancer, 2006, 42, 1434-1440.	1.3	26
232	Incidence of and survival from Wilmsâ€™ tumour in adults in Europe: Data from the EURO CARE study. European Journal of Cancer, 2006, 42, 2363-2368.	1.3	56
233	National survey of British public's views on use of identifiable medical data by the National Cancer Registry. BMJ: British Medical Journal, 2006, 332, 1068-1072.	2.4	88
234	Hodgkin disease survival in Europe and the U.S.. Cancer, 2006, 107, 352-360.	2.0	64

#	ARTICLE	IF	CITATIONS
235	Origins of socio-economic inequalities in cancer survival: a review. <i>Annals of Oncology</i> , 2006, 17, 5-19.	0.6	550
236	Survival trends for small intestinal cancer in England and Wales, 1971â€“1990: national population-based study. <i>British Journal of Cancer</i> , 2006, 95, 1296-1300.	2.9	5
237	Guidelines on confidentiality for population-based cancer registration. <i>European Journal of Cancer Prevention</i> , 2005, 14, 309-327.	0.6	8
238	Guidelines for confidentiality and cancer registration. <i>British Journal of Cancer</i> , 2005, 92, 2095-2096.	2.9	9
239	Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. <i>Gut</i> , 2005, 54, 268-273.	6.1	114
240	Geographical variation in life expectancy at birth in England and Wales is largely explained by deprivation. <i>Journal of Epidemiology and Community Health</i> , 2005, 59, 115-120.	2.0	115
241	Choice of geographic unit influences socioeconomic inequalities in breast cancer survival. <i>British Journal of Cancer</i> , 2005, 92, 1279-1282.	2.9	114
242	Breast cancer survival in South Asian women in England and Wales. <i>Journal of Epidemiology and Community Health</i> , 2005, 59, 402-406.	2.0	38
243	Trends and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkinâ€™s Lymphoma Diagnosed in England and Wales between 1986 and 1999.. <i>Blood</i> , 2005, 106, 749-749.	0.6	5
244	Colon cancer prevalence and estimation of differing care needs of colon cancer patients. <i>Annals of Oncology</i> , 2004, 15, 1136-1142.	0.6	22
245	Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2004, 90, 1367-1373.	2.9	350
246	Breast carcinoma survival in Europe and the United States. <i>Cancer</i> , 2004, 100, 715-722.	2.0	163
247	Explaining gastric cancer survival differences among European countries. <i>International Journal of Cancer</i> , 2004, 109, 737-741.	2.3	75
248	Colorectal cancer survival trends in Norway 1958â€“1997. <i>European Journal of Cancer</i> , 2004, 40, 734-742.	1.3	46
249	Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening. <i>International Journal of Cancer</i> , 2003, 103, 538-543.	2.3	30
250	Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. <i>International Journal of Cancer</i> , 2003, 106, 416-422.	2.3	241
251	The journey towards a cancer diagnosis: the experiences of people with cancer, their family and carers. <i>European Journal of Cancer Care</i> , 2003, 12, 317-326.	0.7	57
252	Cancer survival in European adolescents and young adults. <i>European Journal of Cancer</i> , 2003, 39, 2600-2610.	1.3	84

#	ARTICLE	IF	CITATIONS
253	Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. <i>European Journal of Cancer</i> , 2003, 39, 2214-2222.	1.3	107
254	EUROCARE-3: survival of cancer patients diagnosed 1990-1994 results and commentary. <i>Annals of Oncology</i> , 2003, 14, v61-v118.	0.6	638
255	EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. <i>Annals of Oncology</i> , 2003, 14, v128-v149.	0.6	400
256	Confidentiality and the public interest in medical research - will we ever get it right?. <i>Clinical Medicine</i> , 2003, 3, 219-228.	0.8	41
257	Cancer prevalence in Northern Europe: the EUROPREVAL study. <i>Annals of Oncology</i> , 2003, 14, 946-957.	0.6	18
258	Electronic availability of EUROCARE-3 data: a tool for further analysis. <i>Annals of Oncology</i> , 2003, 14, v150-v155.	0.6	28
259	Cancer prevalence in Central Europe: the EUROPREVAL Study. <i>Annals of Oncology</i> , 2003, 14, 313-322.	0.6	54
260	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. <i>Annals of Oncology</i> , 2003, 14, v14-v27.	0.6	74
261	Childhood cancer survival in Europe. <i>Annals of Oncology</i> , 2003, 14, v119-v127.	0.6	119
262	Cancer Survival in Kentucky and Health Insurance Coverage. <i>Archives of Internal Medicine</i> , 2003, 163, 2135.	4.3	135
263	Cancer control in Europe: A proposed set of European Cancer Health Indicators. <i>European Journal of Public Health</i> , 2003, 13, 116-119.	0.1	23
264	Cancer prevalence in European registry areas. <i>Annals of Oncology</i> , 2002, 13, 840-865.	0.6	164
265	Measuring cancer prevalence in Europe: the EUROPREVAL Project. <i>Annals of Oncology</i> , 2002, 13, 831-839.	0.6	88
266	A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. <i>Annals of Oncology</i> , 2002, 13, 1128-1139.	0.6	30
267	Childhood cancer survival in Europe and the United States. <i>Cancer</i> , 2002, 95, 1767-1772.	2.0	231
268	Coffee consumption and serum aminotransferases in middle-aged Japanese men. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 823-829.	2.4	91
269	Survival of childhood lymphomas in Europe, 1978-1992. <i>European Journal of Cancer</i> , 2001, 37, 703-710.	1.3	31
270	Survival of children with bone sarcoma in Europe since 1978. <i>European Journal of Cancer</i> , 2001, 37, 760-766.	1.3	99



#	ARTICLE	IF	CITATIONS
271	Childhood melanoma in Europe since 1978. <i>European Journal of Cancer</i> , 2001, 37, 780-784.	1.3	62
272	Survival of children with soft-tissue sarcoma in Europe since 1978. <i>European Journal of Cancer</i> , 2001, 37, 767-774.	1.3	56
273	Survival of children with liver tumours in Europe 1978-1989. <i>European Journal of Cancer</i> , 2001, 37, 744-749.	1.3	4
274	Survival of children with thyroid cancer in Europe 1978-1989. <i>European Journal of Cancer</i> , 2001, 37, 775-779.	1.3	13
275	Survival for retinoblastoma in Europe. <i>European Journal of Cancer</i> , 2001, 37, 730-735.	1.3	30
276	Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978-1992. <i>European Journal of Cancer</i> , 2001, 37, 687-694.	1.3	33
277	Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978. <i>European Journal of Cancer</i> , 2001, 37, 695-702.	1.3	16
278	Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992. <i>European Journal of Cancer</i> , 2001, 37, 711-721.	1.3	47
279	Survival of children with Wilms' tumour in Europe. <i>European Journal of Cancer</i> , 2001, 37, 736-743.	1.3	14
280	Cancer survival increases in Europe, but international differences remain wide. <i>European Journal of Cancer</i> , 2001, 37, 1659-1667.	1.3	135
281	Cancer information under threat: The case for legislation. <i>Annals of Oncology</i> , 2001, 12, 145-147.	0.6	8
282	Socioeconomic inequalities in cancer survival in England and Wales. <i>Cancer</i> , 2001, 91, 208-216.	2.0	106
283	Socioeconomic inequalities in cancer survival in England and Wales. <i>Cancer</i> , 2001, 91, 208-216.	2.0	89
284	Extent of misclassification of death from Creutzfeldt-Jakob disease in England 1979-96: retrospective examination of clinical records. <i>BMJ: British Medical Journal</i> , 2000, 320, 145-147.	2.4	13
285	How many deaths have been avoided through improvements in cancer survival?. <i>BMJ: British Medical Journal</i> , 2000, 320, 895-898.	2.4	71
286	Toward a comparison of survival in American and European cancer patients. <i>Cancer</i> , 2000, 89, 893-900.	2.0	129
287	Completeness of cancer registration: a new method for routine use. <i>British Journal of Cancer</i> , 2000, 82, 1111-1116.	2.9	63
288	Trends in breast cancer incidence, survival, and mortality. <i>Lancet, The</i> , 2000, 356, 590-591.	6.3	48

#	ARTICLE	IF	CITATIONS
289	Survival and reduction in mortality from breast cancer. <i>BMJ: British Medical Journal</i> , 2000, 321, 1470-1470.	2.4	8
290	Survival after acute lymphocytic leukaemia: effects of socioeconomic status and geographic region. <i>Archives of Disease in Childhood</i> , 1999, 80, 311-317.	1.0	35
291	Variations in survival for invasive cervical cancer among European women, 1978-89. EURO CARE Working Group. <i>Cancer Causes and Control</i> , 1999, 10, 575-581.	0.8	21
292	Opinion: why the variation in breast cancer survival in Europe?. <i>Breast Cancer Research</i> , 1999, 1, 22-6.	2.2	17
293	Coffee Drinking and Serum Gamma-Glutamyltransferase. <i>Annals of Epidemiology</i> , 1999, 9, 325-331.	0.9	53
294	Survival of women with breast cancer in Europe: Variation with age, year of diagnosis and country. , 1998, 77, 679-683.		80
295	National scientific medical meeting 1997 abstracts. <i>Irish Journal of Medical Science</i> , 1998, 167, 1-44.	0.8	0
296	Variation in survival of patients with lung cancer in Europe, 1985â€“1989. <i>European Journal of Cancer</i> , 1998, 34, 2191-2196.	1.3	135
297	Improved survival for patients with testicular cancer in Europe since 1978. <i>European Journal of Cancer</i> , 1998, 34, 2236-2240.	1.3	34
298	Improving survival of melanoma patients in Europe since 1978. <i>European Journal of Cancer</i> , 1998, 34, 2197-2203.	1.3	20
299	Variation in survival for adults with Nasopharyngeal cancer in Europe, 1978â€“1989. <i>European Journal of Cancer</i> , 1998, 34, 2162-2166.	1.3	27
300	Variations in survival from breast cancer in Europe by age and country, 1978â€“1989. <i>European Journal of Cancer</i> , 1998, 34, 2204-2211.	1.3	52
301	The prognostic role of gender in survival of adult cancer patients. <i>European Journal of Cancer</i> , 1998, 34, 2271-2278.	1.3	135
302	Survival of colorectal cancer patients in Europe during the period 1978â€“1989. <i>European Journal of Cancer</i> , 1998, 34, 2176-2183.	1.3	133
303	Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. <i>European Journal of Cancer</i> , 1998, 34, 2154-2161.	1.3	96
304	Survival of patients with oesophageal and gastric cancers in Europe. <i>European Journal of Cancer</i> , 1998, 34, 2167-2175.	1.3	110
305	Improvement in survival of patients with cancer of the kidney in Europe. <i>European Journal of Cancer</i> , 1998, 34, 2232-2235.	1.3	9
306	The EURO CARE II study. <i>European Journal of Cancer</i> , 1998, 34, 2139-2153.	1.3	61

#	ARTICLE	IF	CITATIONS
307	Survival of adult patients with cancer of soft tissues or bone in Europe. <i>European Journal of Cancer</i> , 1998, 34, 2212-2217.	1.3	37
308	Survival rates for primary malignant brain tumours in Europe. <i>European Journal of Cancer</i> , 1998, 34, 2241-2247.	1.3	33
309	Variation in survival of adult patients with thyroid cancer in Europe. <i>European Journal of Cancer</i> , 1998, 34, 2248-2252.	1.3	42
310	Variation in survival of adult patients with haematological malignancies in Europe since 1978. <i>European Journal of Cancer</i> , 1998, 34, 2253-2263.	1.3	40
311	Excess mortality in England and Wales, and in Greater London, during the 1995 heatwave. <i>Journal of Epidemiology and Community Health</i> , 1998, 52, 482-486.	2.0	240
312	Mortality from dementias and neurodegenerative disorders in people aged 15-64 in England and Wales in 1979-96. <i>BMJ: British Medical Journal</i> , 1998, 317, 320-321.	2.4	3
313	Obesity and ovarian cancer. <i>European Journal of Cancer</i> , 1997, 33, 1529-1531.	1.3	8
314	Safety of tamoxifen. <i>Lancet</i> , The, 1996, 347, 836-837.	6.3	2
315	Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. <i>International Journal of Cancer</i> , 1996, 65, 13-19.	2.3	88
316	Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. , 1996, 65, 13.		12
317	Deprivation, stage at diagnosis and cancer survival. <i>International Journal of Cancer</i> , 1995, 63, 324-329.	2.3	127
318	Deprivation and survival from breast cancer. <i>British Journal of Cancer</i> , 1995, 72, 738-743.	2.9	93
319	The role of cancer registries. <i>Clinical Oncology</i> , 1995, 7, 143-144.	0.6	9
320	The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. <i>Gastroenterology</i> , 1994, 107, 1335-1344.	0.6	57
321	Trends in primary cerebral lymphoma. <i>British Journal of Cancer</i> , 1994, 70, 716-718.	2.9	62
322	An international association between <i>Helicobacter pylori</i> infection and gastric cancer. <i>Lancet</i> , The, 1993, 341, 1359-1363.	6.3	1,134
323	International association between <i>Helicobacter pylori</i> and gastric cancer. <i>Lancet</i> , The, 1993, 342, 120-121.	6.3	14
324	Epidemiology of, and risk factors for, <i>Helicobacter pylori</i> infection among 3194 asymptomatic subjects in 17 populations. The EUROGAST Study Group.. <i>Gut</i> , 1993, 34, 1672-1676.	6.1	382

#	ARTICLE	IF	CITATIONS
325	A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. <i>Atherosclerosis</i> , 1992, 92, 177-185.	0.4	61
326	Breast cancer, blindness and melatonin. <i>European Journal of Cancer</i> , 1992, 28, 501-503.	1.3	53
327	Confidentiality in the cancer registry. <i>British Journal of Cancer</i> , 1992, 66, 1138-1149.	2.9	17
328	Cancer risks related to electricity production. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 1504-1519.	0.9	14
329	Carcinogenicity evaluations and ongoing studies: the IARC databases.. <i>Environmental Health Perspectives</i> , 1991, 96, 5-9.	2.8	29
330	Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type. <i>International Journal of Cancer</i> , 1991, 48, 28-33.	2.3	84
331	Extremely low frequency (ELF) electromagnetic fields and leukaemia in children. <i>British Journal of Cancer</i> , 1990, 62, 331-332.	2.9	8
332	Extremely low-frequency electric and magnetic fields and risk of human cancer. <i>Bioelectromagnetics</i> , 1990, 11, 91-99.	0.9	23
333	Cancer mortality in rio de janeiro. <i>International Journal of Cancer</i> , 1990, 46, 173-177.	2.3	4
334	Cancer and electromagnetic fields. <i>Lancet, The</i> , 1990, 336, 1259.	6.3	4
335	Letter to mutation epidemiologists. <i>Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology</i> , 1989, 216, 91.	0.4	0
336	Radiation dose and breast cancer risk in patients treated for cancer of the cervix. <i>International Journal of Cancer</i> , 1989, 44, 7-16.	2.3	56
337	Leukaemia and residence near electricity transmission equipment: a case-control study. <i>British Journal of Cancer</i> , 1989, 60, 793-798.	2.9	123
338	Journal of clinical epidemiology 1988; 41: 517-518. <i>Journal of Clinical Epidemiology</i> , 1989, 42, 480.	2.4	0
339	Cancer registration in the European Community. <i>International Journal of Cancer</i> , 1988, 42, 339-345.	2.3	20
340	The completeness of cancer registration in England: an assessment from the Oxford-FPA contraceptive study. <i>British Journal of Cancer</i> , 1988, 58, 507-511.	2.9	34
341	Radiation Dose and Second Cancer Risk in Patients Treated for Cancer of the Cervix. <i>Radiation Research</i> , 1988, 116, 3.	0.7	343
342	A Review of Epidemiological Studies of the Health Effects of Living Near or Working with Electricity Generation and Transmission Equipment. <i>International Journal of Epidemiology</i> , 1988, 17, 1-13.	0.9	150

#	ARTICLE	IF	CITATIONS
343	Analysis of leukaemia registration. <i>Journal of Public Health</i> , 1988, 10, 73-74.	1.0	0
344	Hormone-Replacement Therapy and Heart Disease. <i>New England Journal of Medicine</i> , 1987, 316, 1274-1275.	13.9	6
345	The completeness of cancer registration in follow-up studies – A cautionary note. <i>British Journal of Cancer</i> , 1987, 56, 357-359.	2.9	12
346	Mortality among male anaesthetists in the United Kingdom, 1957-83.. <i>BMJ: British Medical Journal</i> , 1987, 295, 360-362.	2.4	45
347	DUAL MEANING OF MEMBERSHIP. <i>Lancet, The</i> , 1987, 330, 265.	6.3	1
348	Multiple primary malignancy in England and Wales, 1971–80: a pilot study of OPCS records. <i>Journal of Public Health</i> , 1987, 9, 15-24.	1.0	0
349	Second malignancies following testicular cancer, ovarian cancer and hodgkin's disease: An international collaborative study among cancer registries. <i>International Journal of Cancer</i> , 1987, 39, 571-585.	2.3	256
350	Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: A population-based cohort study. <i>British Journal of Cancer</i> , 1987, 56, 349-355.	2.9	52
351	Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1987, 94, 620-635.	1.1	284
352	TAMOXIFEN PROPHYLAXIS. <i>Lancet, The</i> , 1986, 327, 263-265.	6.3	3
353	Cancer incidence in Murcia, Spain, in 1982: First results from a population-based cancer registry. <i>International Journal of Cancer</i> , 1986, 38, 1-7.	2.3	6
354	A Plague Epidemic in Voluntary Quarantine. <i>International Journal of Epidemiology</i> , 1986, 15, 379-385.	0.9	7
355	Cohort Study Analysis with a FORTRAN Computer Program. <i>International Journal of Epidemiology</i> , 1986, 15, 134-137.	0.9	251
356	Space-time clustering of nasopharyngeal carcinoma in Greenland Eskimos. <i>British Journal of Cancer</i> , 1985, 52, 909-914.	2.9	6
357	Second Cancers Following Radiation Treatment for Cervical Cancer. An International Collaboration Among Cancer Registries. <i>Journal of the National Cancer Institute</i> , 1985, , .	3.0	101
358	LEUKAEMIA MORTALITY IN AMATEUR RADIO OPERATORS. <i>Lancet, The</i> , 1985, 326, 106-107.	6.3	4
359	LEUKAEMIA INCIDENCE IN ELECTRICAL WORKERS. <i>Lancet, The</i> , 1983, 321, 982-983.	6.3	97
360	CIGARETTE ADVERTISING. <i>Lancet, The</i> , 1982, 320, 1106.	6.3	0

#	ARTICLE	IF	CITATIONS
361	EPIDEMIOLOGY AND THE CLINICIAN. Lancet, The, 1981, 318, 640-641.	6.3	0